ADRA1D: IHC Expression in Cancer and Radioligand Target Profile
ADRA1D, adrenoceptor alpha 1D, is a cell-surface protein (GPCR). In Human Protein Atlas immunohistochemistry, ADRA1D staining is highest in liver cancer (67% of samples positive), prostate cancer (80% of samples positive) and kidney cancer (58% of samples positive). Evidence on whether ADRA1D internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is ADRA1D the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze ADRA1D freeIs ADRA1D a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Medium IHC staining in liver cancer, 67% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
ADRA1D IHC staining by cancer type
Protein expression of ADRA1D across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Liver Cancer | 0.36 | Medium | 67% |
| Prostate Cancer | 0.33 | Medium | 80% |
| Kidney Cancer | 0.25 | Medium | 58% |
| Breast Cancer | 0.19 | Low | 58% |
| Pancreatic Cancer | 0.15 | Low | 46% |
| Colorectal Cancer | 0.14 | Low | 42% |
| Cervical Cancer | 0.12 | Low | 36% |
| Ovarian Cancer | 0.12 | Low | 27% |
| Endometrial Cancer | 0.09 | Low | 27% |
| Melanoma | 0.08 | Low | 25% |
| Testicular Cancer | 0.08 | Low | 25% |
| Gastric Cancer | 0.07 | Low | 22% |
| Lung Cancer | 0.06 | Low | 17% |
| Glioma | 0.03 | Low | 10% |
| Bladder Cancer | 0.03 | Low | 9% |
Not detected by IHC in: skin cancer, head and neck cancer, lymphoma, thyroid cancer, neuroendocrine tumors.
Is ADRA1D internalized?
Uncertain. Insufficient literature found.
ADRA1D clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for ADRA1D yet. Search ClinicalTrials.gov for ADRA1D trials.
ADRA1D normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ADRA1D in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
ADRA1D gene essentiality (DepMap)
CRISPR knockout effect across 1251 cancer cell lines: 0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related liver cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · SSTR2 · STEAP2 · HER2 (ERBB2) · Mesothelin (MSLN) · B7-H3 (CD276)
See all radioligand therapy targets in liver cancer.
See how ADRA1D ranks against 15,000 targets for your indication.
Analyze ADRA1D freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.